Carrie Noran Jaeger, | |
3800 Park Nicollet Blvd, St Louis Park, MN 55416-2527 | |
(952) 993-3708 | |
Not Available |
Full Name | Carrie Noran Jaeger |
---|---|
Gender | Female |
Speciality | Physical Medicine And Rehabilitation |
Experience | 25 Years |
Location | 3800 Park Nicollet Blvd, St Louis Park, Minnesota |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1053398008 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208100000X | Physical Medicine & Rehabilitation | 44372 (Minnesota) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Park Nicollet Methodist Hospital | Saint louis park, MN | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Park Nicollet Clinic | 7911819438 | 1529 |
News Archive
ImmunoCellular Therapeutics, Ltd. announced that updated efficacy and safety data from the phase II trial of dendritic cell-based immunotherapeutic vaccine ICT-107 in patients with newly diagnosed glioblastoma multiforme (GBM) were presented at the 2014 American Society for Clinical Oncology (ASCO) annual meeting in Chicago.
Investigators at Hospital for Special Surgery have identified two new targets for drugs aimed at controlling lupus.
Cardiovascular disease pervades Appalachia, yet many Appalachians live far from any heart and vascular specialist. Follow-up doctor's visits in the weeks after cardiovascular surgery can involve hours-long drives down narrow, winding roads.
Sirion Therapeutics, Inc. announced today that its supplemental New Drug Application (sNDA) submitted to the U.S. Food and Drug Administration (FDA) seeking market approval of Durezol(TM) (difluprednate ophthalmic emulsion) 0.05% to treat endogenous anterior uveitis has been accepted for review.
› Verified 3 days ago
Entity Name | Park Nicollet Clinic |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1780621904 PECOS PAC ID: 7911819438 Enrollment ID: O20031104000046 |
News Archive
ImmunoCellular Therapeutics, Ltd. announced that updated efficacy and safety data from the phase II trial of dendritic cell-based immunotherapeutic vaccine ICT-107 in patients with newly diagnosed glioblastoma multiforme (GBM) were presented at the 2014 American Society for Clinical Oncology (ASCO) annual meeting in Chicago.
Investigators at Hospital for Special Surgery have identified two new targets for drugs aimed at controlling lupus.
Cardiovascular disease pervades Appalachia, yet many Appalachians live far from any heart and vascular specialist. Follow-up doctor's visits in the weeks after cardiovascular surgery can involve hours-long drives down narrow, winding roads.
Sirion Therapeutics, Inc. announced today that its supplemental New Drug Application (sNDA) submitted to the U.S. Food and Drug Administration (FDA) seeking market approval of Durezol(TM) (difluprednate ophthalmic emulsion) 0.05% to treat endogenous anterior uveitis has been accepted for review.
› Verified 3 days ago
Mailing Address | Practice Location Address |
---|---|
Carrie Noran Jaeger, 3800 Park Nicollet Blvd, Credentialing, St Louis Park, MN 55416-2527 Ph: () - | Carrie Noran Jaeger, 3800 Park Nicollet Blvd, St Louis Park, MN 55416-2527 Ph: (952) 993-3708 |
News Archive
ImmunoCellular Therapeutics, Ltd. announced that updated efficacy and safety data from the phase II trial of dendritic cell-based immunotherapeutic vaccine ICT-107 in patients with newly diagnosed glioblastoma multiforme (GBM) were presented at the 2014 American Society for Clinical Oncology (ASCO) annual meeting in Chicago.
Investigators at Hospital for Special Surgery have identified two new targets for drugs aimed at controlling lupus.
Cardiovascular disease pervades Appalachia, yet many Appalachians live far from any heart and vascular specialist. Follow-up doctor's visits in the weeks after cardiovascular surgery can involve hours-long drives down narrow, winding roads.
Sirion Therapeutics, Inc. announced today that its supplemental New Drug Application (sNDA) submitted to the U.S. Food and Drug Administration (FDA) seeking market approval of Durezol(TM) (difluprednate ophthalmic emulsion) 0.05% to treat endogenous anterior uveitis has been accepted for review.
› Verified 3 days ago
David J Nutz, MD Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 3800 Park Nicollet Blvd, St Louis Park, MN 55416 Phone: 952-993-3800 Fax: 952-993-1392 | |
Anne Nadine Maurer, Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 3800 Park Nicollet Blvd, St Louis Park, MN 55416 Phone: 952-993-3800 | |
Amy Stenehjem-kelsch, Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 3800 Park Nicollet Blvd, St Louis Park, MN 55416 Phone: 952-993-3800 | |
Leela Engineer, Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 3800 Park Nicollet Blvd, St Louis Park, MN 55416 Phone: 952-993-3800 | |
Juliette Rosaly Benjamin, Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 3660 Independence Ave S Apt 42, St Louis Park, MN 55426 Phone: 320-455-2603 | |
Raisa Gringauz, M.D. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 4330 Cedar Lake Rd S, St Louis Park, MN 55416 Phone: 952-381-3434 Fax: 952-377-1430 |